Octave Bioscience announced the publication of a real-world clinical utility study in Multiple Sclerosis Journal – Experimental, Translational and Clinical entitled “Real-world clinical utility of a multi-protein, blood-based biomarker assay for disease activity assessments in multiple sclerosis.”
The study evaluated the impact of the Octave MS Disease Activity (MSDA) Test across a diverse range of MS clinical settings to determine how the MSDA Test results informed clinical decision-making.
The Octave MSDA Test, a clinically validated, multi-protein biomarker assay, measures 18 proteins to assess disease activity, enabling neurologists to make more informed decisions regarding disease-modifying therapy (DMT) initiation, switching, and discontinuation. The study examined 352 patient charts that were longitudinally evaluated by 20 clinicians across 14 sites—including academic medical centers, regional hospitals, and community neurology practices—using 723 results from the MSDA Test.
Specific key findings include:
· The result of a single MSDA Test influenced the MS management decision in 59.8% of cases and that influence increased with follow-up use: 69.2% of multiple, longitudinal MSDA Test results influenced clinicians’ care decisions.
· Nearly 1 in 5 (19.4%) results of the MSDA Test led clinicians to adjust MS management.
· The study found three main patterns in how MSDA Test results impacted clinician MS management: 1) a low MSDA Test score supported a clinician’s plan to continue the patient’s current treatment plan; 2) a low MSDA Test score also influenced clinician’s decision to change the treatment plan by discontinuing the patient’s DMT; and 3) a high MSDA Test score led the clinician to change the patient’s treatment plan by initiating or switching their DMT.
